Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders. The company’s novel pipeline is based on Nobel Prize winning research and leverages groundbreaking science to address some of the most urgent diseases in CNS and beyond.
The company has four novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.
Trevena is guided by an innovative spirit and an unwavering commitment to patients. It is a place driven by its employees – passionate and talented industry experts who operate with integrity, transparency, and respect for one another. Trevena employees are united in one mission: to deliver new medicines that address critical needs of patients.